handshake-1
miodrag ignjatovic / iStockphoto.com
18 July 2018Americas

AbbVie and Mylan agree Humira licensing deal

US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
11 May 2021   MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.
Generics
29 April 2021   Mylan can deduct legal fees from defending itself against patent infringement suits as business expenses, according to the US Tax Court.
Americas
8 November 2018   Biotech company Momenta has obtained the rights to use AbbVie’s Humira IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.